Allergan Looks to Boost Migraine Business with MAP Pharmaceuticals Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 1 (Table of Contents)
Published: 28 Jan-2013
DOI: 10.3833/pdr.v2013.i1.1876 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a move to strengthen its neurology franchise, Allergan has agreed to acquire MAP Pharmaceuticals, developer of the acute migraine drug Levadex® (dihydroergotamine) inhalation aerosol, in a deal that values the company at approximately US$958 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS